



January 4, 2016

## BioCryst to Present at the J.P. Morgan Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2016 (GLOBE NEWSWIRE) -- [BioCryst Pharmaceuticals, Inc.](#) (NASDAQ:BCRX) today announced that [executives from BioCryst](#) are scheduled to present and provide a corporate summary and update regarding the Company's development programs at the 34<sup>th</sup> annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 13, 2016 at 9:00 a.m. Pacific Time.

Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at <http://investor.shareholder.com/biocryst/events.cfm>.

### About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst's ongoing development programs include oral plasma kallikrein inhibitors for hereditary angioedema; [avoralstat](#), BCX7353 and other second generation compounds, and [BCX4430](#), a broad spectrum viral RNA polymerase inhibitor. For more information, please visit the Company's website at [www.BioCryst.com](http://www.BioCryst.com).

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at <http://investor.shareholder.com/biocryst/sec.cfm>.

BCRXW

Â

CONTACT: Robert Bennett, BioCryst Pharmaceuticals, +1-919-859-7910

 [Primary Logo](#)

Source: Biocryst Pharmaceuticals

News Provided by Acquire Media